

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection
Details : Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Product Name : Tirofiban Hydrochloride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 09, 2023
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tirofiban is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ischemic Stroke.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Aspirin,Clopidogrel
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves...
Product Name : Aggrastat
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Aspirin,Clopidogrel
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT
Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...
Product Name : Aggrastat
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Tirofiban Hydrochloride Monohydrate,Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tirofiban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
Correvio Partners with Hong Kong Teson Pharma Limited
Details : The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $3.0 million
March 10, 2020
Lead Product(s) : Tirofiban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tirofiban
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tirofiban is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2013
Lead Product(s) : Tirofiban
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency
Details : Tirofiban is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 15, 2012
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : SCRI Development Innovations, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Details : Tirofiban is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 31, 2012
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : SCRI Development Innovations, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
